Concept:
Neonatal hyperbilirubinemia is a major neurotoxic risk factor for the auditory system, having a specific selective predilection for injuring the cochlear nuclei in the brainstem and the eighth cranial nerve (vestibulocochlear nerve).
This distinct clinical pathology is recognized as Auditory Neuropathy Spectrum Disorder (ANSD).
Explanation:
• Universal newborn hearing screening employs two main physiological technologies: Otoacoustic Emissions (OAE) and Automated Auditory Brainstem Response (AABR).
• Otoacoustic Emissions (OAE): Measures sound waves generated by the contractile motion of outer hair cells (OHCs) in the cochlea. It only assesses the pre-neural cochlear amplifier mechanism.
• Auditory Brainstem Response (ABR BERA): Measures electrophysiological neural conduction along the eighth cranial nerve through the brainstem auditory pathways (cochlear nucleus, superior olivary complex, lateral lemniscus, and inferior colliculus).
• In bilirubin-induced auditory neurotoxicity (ANSD), the outer hair cells of the cochlea remain entirely intact and functional (hence, OAE is completely normal "pass"), while synaptic transmission from inner hair cells or neural conduction along the auditory nerve/brainstem is severely disrupted.
• Consequently, relying solely on OAE in infants with hyperbilirubinemia or NICU stays will falsely miss ANSD.
• Therefore, Diagnostic Brainstem Evoked Response Audiometry (BERA/ABR) is the mandatory next investigation to evaluate neural auditory pathway function.
Final Answer:
Brainstem Evoked Response Audiometry (BERA/ABR) is the next best investigation to diagnose auditory neuropathy spectrum disorder in an infant with hyperbilirubinemia and normal OAE.